نتایج جستجو برای: cyp2c19

تعداد نتایج: 2034  

Journal: :Biological & pharmaceutical bulletin 2009
Yohei Yanagida Minoru Watanabe Yuko Takeba Toshio Kumai Naoki Matsumoto Mikihito Hayashi Satoshi Suzuki Yuichi Kinoshita Shinichi Kobayashi

Cytochrome P450 (CYP) 3A enzymes are responsible for the metabolism of many drugs. It is useful to know CYP3A activity in individual patients undergoing drug therapy so as to predict the efficacies or adverse events. Lansoprazole is metabolized to Lansoprazole sulfone (LS) by CYP3A, while to 5-hydroxylansoprasole by CYP2C19. The aim of this study was to evaluate whether lansoprazole can be used...

2014
Hyunsik Jung Sanghun Lee

Objective. Potential interactions between herbal extracts and the cytochrome P450 (CYP) system lead to serious adverse events or decreased drug efficacy. Rhus verniciflua stoke (RVS) and its constituents have been reported to have various pharmacological properties. We evaluated the inhibitory potential of RVS and its constituents on the major CYP isoforms. Methods. The effects of allergen remo...

Journal: :BMC Clinical Pharmacology 2007
Carlos Isaza Julieta Henao José H Isaza Martínez Juan C Sepúlveda Arias Leonardo Beltrán

BACKGROUND Omeprazole is metabolized by the hepatic cytochrome P450 (CYP) 2C19 enzyme to 5-hydroxyomeprazole. CYP2C19 exhibits genetic polymorphisms responsible for the presence of poor metabolizers (PMs), intermediate metabolizers (IMs) and extensive metabolizers (EMs). The defective mutations of the enzyme and their frequencies change between different ethnic groups; however, the polymorphism...

2016
Geik Yong Ang Choo Yee Yu Vinothini Subramaniam Mohd Ikhmal Hanif Abdul Khalid Tuan Azlin Tuan Abdu Aziz Richard Johari James Aminuddin Ahmad Thuhairah Abdul Rahman Fadzilah Mohd Nor Adzrool Idzwan Ismail Kamarudzaman Md. Isa Hood Salleh Lay Kek Teh Mohd Zaki Salleh

The human cytochrome P450 (CYP) is a superfamily of enzymes that have been a focus in research for decades due to their prominent role in drug metabolism. CYP2C is one of the major subfamilies which metabolize more than 10% of all clinically used drugs. In the context of CYP2C19, several key genetic variations that alter the enzyme's activity have been identified and catalogued in the CYP allel...

Journal: :The Indian journal of medical research 2009
A S Chaudhry R Kochhar K K Kohli

BACKGROUND & OBJECTIVES Genetic polymorphism of CYP2C19 is known to occur with a frequency of 12 per cent in north Indian population. But no study correlated CYP2C19 genetic polymorphism with eradication of Helicobacter pylori in north Indian gastritis patients positive for H. pylori and hence this study. METHODS Ninety one consecutive patients positive for H. pylori fulfilling the study crit...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2006
Carole Giraud Jean-Marc Treluyer Elisabeth Rey Catherine Chiron Jean Vincent Gérard Pons Agnès Tran

A metabolic interaction between stiripentol (STP), an anticonvulsant agent that inhibits the activity of several cytochromes P450 (P450s), and clobazam (CLB), a 1,5-benzodiazepine, used in association with STP in severe myoclonic epilepsy in infancy was observed in vivo. This interaction was characterized in vitro using cDNA-expressed CYP3A4 and CYP2C19 (main P450 involved in CLB metabolism) to...

2012
Nuala Ann Helsby Kathryn Elisa Burns

Inherited variation in the function of the drug metabolizing enzyme CYP2C19 was first observed 40 years ago. The SNP variants which underpin loss of CYP2C19 function have been elucidated and extensively studied in healthy populations. However, there has been relatively meagre translation of this information into the clinic. The presence of genotype-phenotype discordance in certain patients sugg...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2012
Tatyana Zvyaga Shu-Ying Chang Cliff Chen Zheng Yang Ragini Vuppugalla Jeremy Hurley Denise Thorndike Andrew Wagner Anjaneya Chimalakonda A David Rodrigues

Six proton pump inhibitors (PPIs), omeprazole, lansoprazole, esomeprazole, dexlansoprazole, pantoprazole, and rabeprazole, were shown to be weak inhibitors of cytochromes P450 (CYP3A4, -2B6, -2D6, -2C9, -2C8, and -1A2) in human liver microsomes. In most cases, IC₅₀ values were greater than 40 μM, except for dexlansoprazole and lansoprazole with CYP1A2 (IC₅₀ = ∼8 μM) and esomeprazole with CYP2C8...

2015
You-quan Wei Dian-gang Wang Hao Yang Heng Cao Carmine Pizzi

BACKGROUND The cytochrome P450 (CYP450) 2C19 681 genotypes affect the antiplatelet activity of clopidogrel. We investigated the correlation of CYP 2C19 681G > A mutation with clopidogrel resistance (CR). Additionally, we studied the effect of CR on clinical prognosis of patients with acute coronary syndrome (ACS). METHODS One hundred ten ACS patients undergoing percutaneous coronary intervent...

2017
J.F.M. Marchini M.R. Pinto G.C. Novaes A.V. Badran R.B. Pavão G.L. Figueiredo I.M. Lago M.O. Lima-Filho D.C. Lemos M. Tonani C.M. Antloga L. Oliveira J.C. Lorenzi J.A. Marin-Neto

Clopidogrel and aspirin are the most commonly used medications worldwide for dual antiplatelet therapy after percutaneous coronary intervention. However, clopidogrel hyporesponsiveness related to gene polymorphisms is a concern. Populations with higher degrees of genetic admixture may have increased prevalence of clopidogrel hyporesponsiveness. To assess this, we genotyped CYP2C19, ABCB1, and P...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید